

## CTI supports Numab's pipeline with CHF 895'000

**Wädenswil, Switzerland, March 6, 2012** – Numab AG, a Swiss Biotech company, today announces the approval of a research grant from the Swiss Commission for Technology and Innovation (CTI). The CTI supports Numab's research on antibody-based approaches for the therapy of ion channel-driven health disorders with a grant of CHF 895'000. Numab is conducting the research activities within this project in collaboration with the Zürich University of applied Sciences (ZHAW).

David Urech, CSO, co-CEO and co-founder of Numab, commented: "With the assignment of this grant, the CTI acknowledges the potential of Numab's technology for the discovery of ion-channel modulators. We are excited about this project, which may give raise to a break-through in antibody-based therapies". Oliver Middendorp, CBO, co-CEO and co-founder of Numab added: "This grant is a great opportunity for Numab, since the project directly adds to Numab's proprietary pipeline and thereby to corporate value."

About Numab AG:

Numab is a privately-owned Swiss biotech company located in Wädenswil, Zürich. The Company is managed by an experienced team and applies its proprietary breakthrough antibody discovery technology to offer first class antibody discovery to the pharmaceutical industry and to pursue proprietary development projects. Numab's breakthrough antibody discovery technology has been deliberately designed to approach complex integral membrane proteins such as GPCRs or ion channels, both major drug target classes that are not amenable to conventional antibody technologies. Traditionally, these target classes have been approached by small molecule drugs. Their use as therapeutics is, however, oftentimes limited by inadequate target specificities frequently resulting in treatment-limiting adverse effects. In contrast, antibodies are generally highly specific for their target thereby passing the shortcomings of small molecule drugs. In summary, Numab's technology allows exploiting the advantages of antibodies for a broader range of targets.

For further information please contact:

Oliver Middendorp  
[o.middendorp@numab.com](mailto:o.middendorp@numab.com)

or visit:

[www.numab.com](http://www.numab.com)